BUSINESS
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC BusinessWednesday, September 30, 2026 at 10:40 PM
RedScroll Brief
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
RedScroll Signal
- Impact
- High
- Category
- Business
- Market relevance
- High
- Why it matters
- Corporate and market moves reprice risk and reveal where power and cash are concentrating. Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year. Investors will watch earnings, rates, and competitive positioning connected to Eli Lilly and Business.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating.
Background
CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
CNBC Business published: Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Investors will watch earnings, rates, and competitive positioning connected to Eli Lilly and Business.
More on
Related stories
- People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
CNBC BusinessBUSINESS
- Travelodge failed sex assault victim 'at every stage'
BBC BusinessBUSINESS
- Regulating AI 'not the right place to start' says Bailey
BBC BusinessBUSINESS
- Fed's Kashkari says inflation is 'still too high' even after softer-than-expected PCE data, labor market is 'pretty good'
CNBC FinanceBUSINESS
- Stellantis CEO reconfirms 2026 guidance, says turnaround plan continues as automaker's shares hit new low
CNBC BusinessBUSINESS
- Ford CEO says it's 'too late' for Europe to fend off Chinese automakers, but not for U.S.
CNBC BusinessBUSINESS
Source
CNBC Business
Original reporting by CNBC Business. RedScroll provides an extractive briefing only.